Magnus Doverskog

Chief Executive Officer

MSc in Organic Chemistry, PhD in Biotechnology from the Royal Institute of Technology (KTH) in Stockholm, and eMBA from the Stockholm University School of Business, has more than 20 years industry experience from discovery and development projects of both small molecules and biologics. Senior positions at Astra Pain Control, Biovitrum AB, and as CEO of IMED AB.

Eva Arlander

Chief Development Officer


MSc Pharm, PhD. Extensive experience from the pharmaceutical industry e.g., AstraZeneca, Medivir and Affibody with main focus on clinical development. Led the development of products from phase 2 to commercialization in EU and US in smaller pharma environments. Experience from leadership and executive in pharma companies and at the Swedish MPA.


Hans Christopher Toll 

Chief Financial Officer

MSc. More than 25 years international experience as business controller and CFO. Embedded consultant in the IPO of Cedegrenska AB at Nasdaq First North (May 2021). Previous CFO roles include KIN Group (Ur & Penn, Lucardi, Kijkshop) FundedByme, DanaherMotion (manufacturing; Switzerland)

Lars Öhman 

Chief Business Officer


MBA. More than 25 years wide-ranging research and business experience in senior positions at Karo Bio AB and Pharmacia. Proven track record in drug discovery and business development within the pharmaceutical industry. Responsible for in- and out-licensing of drug discovery and development projects to the pharmaceutical industry at Karo Bio during 2004-2012.